Calcium Hypophosphite Market is Estimated to Witness High Growth Owing to its Extensive Application in Various End-Use Industries

cmigauri

posted on 7 months ago — updated on 2 seconds ago

65
views

Calcium Hypophosphite Market is Estimated to Witness High Growth Owing to its Extensive Application in Various End-Use Industries

The global Calcium Hypophosphite Market is estimated to be valued at US$ 259.67 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Calcium hypophosphite is an inorganic compound that is widely used as a reducing agent, catalyst, and stabilizer. It serves as a binder in steel manufacturing and prevents oxidation during high-temperature treatment. Calcium hypophosphite is also used as a flame retardant in various materials. It acts as an effective reducing agent in organic synthesis by incorporating phosphorus into organic molecules.

Market Opportunity: Extensive Application in Various End-Use Industries

The extensive application of calcium hypophosphite in various end-use industries such as iron and steel, chemicals, chemical intermediate industry, petrochemicals, is expected to drive the market growth over the forecast period. In the iron and steel industry, it acts as a binder and prevents oxidation at high temperatures. Calcium hypophosphite also finds application as a flame retardant in construction and electronics industry. Moreover, it is used as a reducing agent and catalyst in chemical industry. The compound has gained significant importance due to its effectiveness in organic synthesis processes. Its incorporation of phosphorus into organic molecules broadens its application spectrum in pharmaceuticals and agrochemical industries as well. The versatile functionality and widespread end-use is estimated to offer lucrative market opportunity for calcium hypophosphite over the coming years.

Porter’s Analysis
Threat of new entrants: The Calcium Hypophosphite market has moderate threat of new entrants due to the availability of wide range of options and substitutes in the market. However, the requirement of high initial investments and certifications creates barriers.
Bargaining power of buyers: The bargaining power of buyers is moderate in this market as the buyers have a variety of vendors to choose from.
Bargaining power of suppliers: The bargaining power of suppliers is moderate due to the presence of a large number of suppliers in the market. However, shift towards branded and certified products increases their power.
Threat of new substitutes: The threat of substitutes is high for Calcium Hypophosphite as there are numerous chemical substitutes available that provide similar functionality at lower costs.
Competitive rivalry: The competitive rivalry is high among existing vendors to sustain and grow in this steadily growing market.

SWOT Analysis
Strength: Calcium Hypophosphite is an important chemical intermediate that finds wide applications. It is inexpensive to produce and stable under normal conditions.
Weakness: Concerns about the impact of Calcium Hypophosphite on the environment and health at high levels. Strict regulations regarding its production and use.
Opportunity: Growing demand for food preservatives and increasing need for flame retardants provide opportunities for market players. Technical advancements help improve efficiency.
Threats: Volatility in raw material prices and availability. Presence of substitutes poses threat.

Key Takeaways
Global Calcium Hypophosphite Market Size is expected to witness high growth during the forecast period of 2024 to 2031. The market size for 2024 is projected to reach US$ 259.67 Bn with a CAGR of 12.%. Regional analysis indicates North America and Europe will continue to dominate the market throughout the forecast period owing to the large food and industrial sectors in these regions demanding Calcium Hypophosphite.

Key players operating in the Calcium Hypophosphite market are Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Amneal Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Viatris Inc.